Ticagrelor Intermediate: Common Difficulties Encountered by Buyers During Sourcing in China & HiSiaddi’s Solutions

As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials from multiple well-known original manufacturers for Ticagrelor Intermediate. As a foreign trade enterprise with R&D capabilities, HiSiaddi will systematically sort out common difficulties faced by B-end buyers sourcing Ticagrelor Intermediate in China and propose targeted solutions from a professional perspective.

If you require more professional and in-depth analysis regarding the procurement of Ticagrelor Intermediate, please contact HiSiaddi’s customer service team.

I. European & American High-End Generic API Pharmaceutical Enterprises (Focused on ANDA Registration & Drug Consistency Evaluation)

(I) Core Pain Points

Excessive chiral isomers leading to registration failures, fluctuating batch racemization rates undermining mass production consistency, residual solvents exceeding ICH limits, catalytic metal residues causing pharmacopoeia non-compliance, and material degradation under high-temperature processes reducing synthetic yields

1. This intermediate contains multiple chiral sites; conventional production processes cannot precisely control stereoconfiguration, easily generating toxic non-target isomers. Once isomer content exceeds the 0.1% limit, the impurity profile of final APIs fails to meet EP and USP pharmacopoeia standards, directly resulting in ANDA registration rejection and on-site audit failures.

2. Non-standard temperature control and crystallization parameters during production lead to significant racemization discrepancies across batches. Clients applying fixed synthetic processes face persistent fluctuations in API purity and impurity content, making it impossible to pass European and American drug consistency evaluations and achieve commercial mass production.

3. The synthetic workflow includes nitration steps; low-grade products tend to retain nitro by-products and alcohol-ester solvents, with multiple residual solvent indicators breaching ICH Q3C specified limits, posing medication safety hazards and barring market access to mainstream European and American markets.

4. Palladium-carbon, nickel-based hydrogenation catalysts are used in production; simplified impurity removal procedures lead to excessive metal residues that transfer to final APIs, triggering pharmacopoeia heavy metal disqualification and full-batch scrapping.

5. Heterocyclic structures exhibit poor thermal stability and are prone to ring-opening and degradation during downstream high-temperature coupling and recrystallization refining steps. This drastically reduces main product yield and generates large volumes of unknown impurities, pushing up overall production costs.

(II) Targeted Solutions

1. Adopt dynamic chiral resolution paired with low-temperature setting crystallization technology to stabilize chiral isomer content below 0.05%, fully meeting European and American pharmacopoeia requirements and ensuring smooth completion of client registration filings and on-site audits.

2. Deploy a full-process closed-loop temperature control system with unified key parameters such as crystallization rates, limiting batch-to-batch racemization discrepancies within 0.03% to stabilize API finished product quality and satisfy consistency evaluation criteria.

3. Apply multi-stage negative pressure rectification and solvent displacement technology to completely strip nitro by-products and all residual solvents, bringing all indicators fully in line with ICH Q3C standards for comprehensive compliance.

4. Add dedicated heavy metal chelation and precision filtration procedures to control palladium, nickel and other catalytic residues within safe ppm ranges, eliminating risks of API heavy metal disqualification at the source.

5. Conduct structural stabilization modification on intermediates to enhance high-temperature resistance and anti-degradation performance, adapting to downstream high-temperature reaction conditions, effectively lifting API synthetic yields and reducing unknown impurity generation.

II. European & American Professional CDMO Custom Synthesis Manufacturers (Undertaking Fragment Synthesis, Process Scale-Up & Customized Material Production)

(I) Core Pain Points

Physical and chemical indicators mismatching customized processes, significant performance gaps between small trial and mass production batches, incomplete impurity data preventing process validation, acid-base residues triggering coupling side reactions, and delayed deliveries disrupting project schedules

1. Different CDMOs adopt distinct synthetic routes, reaction temperatures and condensation systems. Fixed purity, water content and pH parameters of generic intermediates fail to match clients’ customized processes, directly causing coupling reaction failures in small trials and project rework.

2. Most suppliers adopt refined small-trial processes but relax control standards upon scale-up, resulting in elevated isomers and impurities, creating a "qualified small trial, failed pilot production" scenario that severely delays project timelines.

3. Only simple certificates of analysis are provided, lacking full impurity traceability, degradation studies and methodology validation data. CDMOs cannot complete process document filing and validation work, making it impossible to deliver finished results to end pharmaceutical clients.

4. Substandard material pH values and trace residual additives undergo antagonistic reactions with condensing agents and pH regulators used on client sites, generating massive by-products and drastically cutting coupling conversion rates.

5. Tight production scheduling and occasional environmental production restrictions in the pharmaceutical intermediate industry lead to frequent delivery cycle changes, forcing delays to established CDMO project milestones and creating contract breach risks.

(II) Targeted Solutions

1. Support flexible customization of full physical and chemical indicators; purity, water content, chiral ratio, pH and other parameters can be adjusted according to client small trial and pilot production process requirements for precise alignment with proprietary synthetic systems.

2. Unify full-process parameters for small trials, pilot production and mass production; continuous flow synthesis technology narrows batch discrepancies to guarantee zero abnormalities during process scale-up.

3. Supply complete impurity analysis reports, traceability materials and stability study data alongside goods to fully support CDMO process validation, document filing and client audits.

4. Perform neutral pH adjustment treatment on materials to completely remove residual additives, ensuring compatibility with all mainstream reaction systems, eliminating antagonistic side reactions and stabilizing coupling conversion rates.

5. Reserve dedicated flexible production capacity for CDMO clients with fixed delivery cycle locks and priority scheduling to guarantee on-time delivery of project milestones.

III. Large-Scale Generic Pharmaceutical Enterprises in Southeast Asia & India (Prioritizing Mass Production & Cost Control)

(I) Core Pain Points

High procurement costs of high-purity raw materials squeezing profit margins, elevated scrap rates from high-impurity low-cost materials, uneven quality across large supply batches requiring repeated parameter adjustments, material degradation and discoloration under high-temperature & high-humidity ocean shipping, and insufficient basic compliance documents preventing local filing

1. High-purity intermediates compliant with European and American standards carry premium pricing; full procurement drastically compresses generic drug profit margins, while low-cost inferior materials fail to meet local pharmacopoeia standards, creating a dilemma balancing cost and quality.

2. Economical raw materials feature weak chiral control and high by-product impurity levels, intensifying downstream purification pressure during client mass production and sustaining elevated finished product disqualification rates with persistent hidden production costs.

3. Large-batch supply exhibits obvious fluctuations in purity and isomer content across batches, requiring repeated production parameter adjustments on manufacturing lines, reducing effective equipment operating time and capacity utilization rates.

4. Heterocyclic structures are sensitive to temperature and humidity; conventional packaging leads to yellowing, gradual degradation of active ingredients and downgraded quality upon arrival after ocean shipping in high-temperature & high-humidity environments.

5. Lack of English test certificates, chromatograms and compliance statements prevents compliance with local pharmaceutical authority filing and routine sampling inspection requirements in India and Southeast Asia.

(II) Targeted Solutions

1. Launch dedicated economical production grades with all indicators meeting local pharmacopoeia access standards at prices far lower than European and American high-purity grades, balancing quality and cost to boost profit margins of client finished drugs.

2. Optimize purification processes for economical products with strict control of high-risk impurities to reduce downstream purification burdens and product scrap rates for stable low-cost mass production.

3. Implement standardized locked-parameter production for mass manufacturing to narrow batch-to-batch indicator gaps, enabling clients to maintain fixed production parameters long-term without frequent adjustments and maximize capacity utilization.

4. Adopt light-shielded, moisture-proof sealed packaging paired with material stabilization treatment to withstand complex ocean shipping environments without degradation, discoloration or active ingredient attenuation upon arrival.

5. Supply streamlined English compliance document packages including certificates of analysis, HPLC chromatograms, quality inspection reports and compliance statements to fully satisfy local pharmaceutical authority filing and routine sampling inspection requirements.

IV. Clinical-Stage CROs & Innovative Pharmaceutical Enterprises (For IND Filing, Phase I/II Clinical Sample Preparation & New Drug Process R&D)

(I) Core Pain Points

Scarce supply of ultra-high purity R&D-grade materials, trace unknown impurities interfering with clinical trial data, excessive premiums for small-batch procurement, delayed scheduling for small orders hindering clinical milestones, and insufficient technical data hampering registration document compilation

1. Clinical sample and new drug R&D demand ultra-high purity materials with minimal isomers and trace impurities; conventional commercial-grade products on the market feature complex impurity systems that disrupt efficacy and safety evaluation results.

2. Some suppliers cannot complete full qualitative impurity analysis; residual trace unknown impurities in materials carry clinical safety risks and create gaps in IND registration documentation.

3. High minimum order quantities are standard across the industry with steep price surcharges for gram and hundred-gram small R&D orders, significantly raising trial-and-error costs for new drug R&D.

4. Suppliers prioritize mass commercial orders, leading to delayed scheduling for small R&D batches that directly hold back clinical sample preparation, experimental iteration and registration progress.

5. Insufficient R&D data including stability studies, impurity research and methodology validation prevents clients from constructing complete IND registration document systems.

(II) Targeted Solutions

1. Develop an ultra-high purity R&D-grade product line with in-depth stripping of isomers and all trace impurities to meet clinical R&D standards for sample preparation and new process research scenarios.

2. Provide full qualitative and quantitative impurity analysis alongside safety assessment services and complete impurity traceability analysis to eliminate clinical data interference and registration risks.

3. Relax small-batch procurement restrictions with support for 10g–1kg orders without additional small-order surcharges to effectively reduce R&D costs.

4. Launch priority scheduling channels for CRO clients to shorten delivery lead times and guarantee on-schedule progress of clinical trials and registration filings.

5. Supply complete R&D data packages covering stability data, impurity research reports and methodology validation materials directly usable for IND registration document integration.

V. Overseas Pharmaceutical Chemical Trading & Repackaging Distributors (Engaged in Intermediate Distribution, Repackaging & Regional Channel Supply)

(I) Core Pain Points

Inferior raw materials with falsely labeled indicators flooding the market, uneven quality post-repackaging caused by component sedimentation in large packages, moisture absorption triggering material degradation during ocean shipping, limited market coverage due to lack of high-end compliance documents, and lost high-quality clients without authoritative test reports

1. Unscrupulous suppliers in the market deliberately inflate chiral purity and main content indicators to seize market share at low prices. After clients commence production, excessive isomers and finished product scrapping trigger extensive after-sales disputes and damage channel reputation.

2. Long-term static storage of large-package materials causes component sedimentation and indicator stratification; simple stirring fails to achieve homogeneity, leading to inconsistent quality across small-specification repackaged batches.

3. Insufficient packaging tightness enables moisture absorption during ocean shipping, accelerating material degradation, reducing active ingredient content and elevating impurity levels resulting in failed acceptance upon arrival.

4. Lack of English SDS, REACH screening and hazardous goods transportation identification documents restricts access to formal European and American pharmaceutical enterprises, limiting business to low-end circulation markets only.

5. Absence of authoritative third-party test reports and complete batch traceability materials prevents passing supplier audits by high-end clients, forfeiting long-term cooperation opportunities.

(II) Targeted Solutions

1. Supply genuine original manufacturer materials with truthfully labeled physical and chemical indicators; every batch comes with authoritative third-party test reports supporting global re-inspection to eliminate adulteration and false labeling risks and avoid after-sales disputes.

2. Implement full-automatic homogenization circulation treatment prior to factory release paired with standardized repackaging workflows to completely resolve component sedimentation issues, ensuring consistent indicators between large and small packages.

3. Adopt vacuum light-shielded moisture-proof sealed packaging to isolate moisture and high temperatures, maintaining stable material performance throughout ocean shipping and warehousing with arrival quality matching factory release standards.

4. Provide a one-stop complete set of English compliance documents including safety data sheets, regulatory screening reports and transportation identification files to facilitate market expansion into high-end European and American markets.

5. Establish a complete batch traceability system with full-item test certificates to satisfy factory audits and review requirements of high-end clients, supporting distributors to expand high-quality cooperation resources.

For more professional and in-depth analysis regarding the procurement of Ticagrelor Intermediate, please contact HiSiaddi’s customer service team.

Lead time

The monthly inventory volume of Ticagrelor Intermediate is 3 tons, with appropriate adjustments upwards or downwards in response to peak and off-peak seasons.

HiSiaddi safeguards the supply stability of Ticagrelor Intermediate through the following measures:

1. Supply of one mainstream Ticagrelor Intermediate model by 3 premium factories

(1) Performance evaluation and screening of Ticagrelor Intermediate brand factories based on on-time delivery rate, batch pass rate, timeliness of risk alerts, and completeness of documentation to assess their supply stability.

(2) For each mainstream model or major grade of Ticagrelor Intermediate, secure 1 primary high-quality brand manufacturer and 2 backup high-quality manufacturers.

(3) Each factory operates independent production lines in separate production zones to prevent production halts caused by major unforeseen incidents such as environmental production suspensions and power outages.

2. Technological transformation partnerships and long-term sales binding for Ticagrelor Intermediate

Through long-term cooperation with brand manufacturers via technology commercialization and authorized distribution channels, HiSiaddi can effectively strengthen supervision over the production processes of brand manufacturers, optimize full-process traceability management, improve batch stability control, and further reinforce real-time monitoring of the supply stability of Ticagrelor Intermediate products.

Long-term Annual Framework Supply Guarantee Agreement. HiSiaddi signs 12-month long-term agreements with leading manufacturers. The agreements specify the minimum guaranteed supply volume, maximum price hike range, and priority production scheduling rights during peak seasons. It is stipulated that manufacturers shall issue a 30-day prior written notice if production is suspended due to environmental rectification or equipment maintenance, and backup manufacturers will be activated to replenish goods accordingly.

3. 4 warehouses and 3 peak & off-peak demand forecasting

We have 4 warehouses, which are jointly operated and managed with suppliers to store hot-selling products.The four warehouses are located at Qingdao Port in North China, Ningbo Port in East China, Shenzhen Port in South China, and Zhengzhou, China’s inland logistics hub. This setup guarantees sufficient supply and timely shipment of Ticagrelor Intermediate during peak seasons.

HiSiaddi issues a rolling demand forecast covering the subsequent three months on the 25th of each month, allowing manufacturers to reserve production capacity in accordance with the forecast. Any new urgent orders from overseas clients will be prioritized to draw on inventories or production capacity from backup manufacturers.

4. Multi-channel logistics to resolve vessel congestion and inspection delays for Ticagrelor Intermediate sea and land shipments

Unstable logistics for Ticagrelor Intermediate will extend delivery lead times. HiSiaddi has established alternative arrangements covering multiple freight forwarders, ports and transportation solutions:

(1) Binding of multiple professional chemical freight forwarders for Ticagrelor Intermediate

Each product is assigned 2 to 3 freight forwarders with hazardous chemical/food transport qualifications affiliated with different shipping lines. Alternative sailing schedules can be switched to immediately in case of space shortages or customs inspections on a single shipping route.

(2) Backup transportation solutions for Ticagrelor Intermediate

Ocean freight serves as the standard mode; air freight and rail freight are reserved as alternatives for urgent orders. Long-term agreements for temperature-controlled containers are signed for temperature-sensitive and perishable food additives to secure shipping space.

(3) Visual tracking and digital early warning for Ticagrelor Intermediate

Freight forwarders synchronize daily updates on container loading, customs declaration, vessel loading and port arrival milestones. If customs inspection occurs, replenishment from backup inventory will be initiated immediately to shorten client waiting periods.

Full-chain digital early warning automatically monitors four categories of risks:

• Factory side: Expiring supplier environmental assessment certificates, renewal of production permits, scheduled major equipment overhauls, and notifications of price hikes for upstream raw materials;

• Inventory side: Inventory falling below safety thresholds, excessive inventory age, and batches failing quality inspection;

• Logistics side: Shipping line space shortages, strikes at destination ports, and updates to customs policies;

• Overseas side: Revisions to additive regulations and adjustments to import restriction lists in target countries.

Early warning notifications are automatically pushed to procurement and business leads, allowing backup suppliers or inventory contingency plans to be activated in advance.

Ticagrelor Intermediate: What Certifications Have Leading Chinese Brands Obtained? What Is Their Market Reception?

HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export services. It has built a service system of "1+2+3+4=1" and can supply Ticagrelor Intermediate sourced directly from multiple well-known original manufacturers.

As an export service provider with independent R&D capabilities, HiSiaddi differs from single-brand manufacturers that only promote their own products. We provide objective analysis of multiple top Chinese manufacturers with strong global export competitiveness, sharing their certification portfolios and market feedback to streamline buyers’ supplier selection process.

For more authentic, objective information on multiple well-known Chinese Ticagrelor Intermediate brands, please contact HiSiaddi customer service.

I. Jiangxi Synergy Pharmaceutical: Global Market Share Leader, Benchmark Supplier for High-End Markets

Core Mainstream Grades

· TH-001: (1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamine hydrochloride, 99.9% enantiomeric purity. Targeted at European and American high-end markets, compatible with originator production and ANDA filings.

· TH-002: Standard grade with 99.5% chemical purity, supplied to generic manufacturers in India and Southeast Asia.

· TH-003: Custom impurity-controlled grade with single impurity ≤0.05%, serving EU CEP-certified API manufacturers.

Core Market Feedback (Verified Reviews from Global Overseas Clients)

1. Top European and American API manufacturers (e.g., Merck Germany, Novartis Switzerland): TH-001 delivers industry-leading enantiomeric stability with inter-batch enantiomeric purity fluctuations limited to ≤0.05%, zero quality complaints over three consecutive years, ranking among the handful of Chinese manufacturers capable of consistent originator-grade intermediate supply.

2. Indian generic giants (e.g., Dr. Reddy’s): High praise for cost-performance and delivery efficiency. TH-002 is priced 42% lower than European and American equivalents with stable lead times ≤12 days, driving a 58% year-on-year purchasing volume increase in 2025.

3. Global CDMO enterprises: Exceptional controllability of impurity profiles enables customized impurity matching to client API production requirements, cutting downstream rework rates. Custom orders accounted for 35% of total sales volume in 2025.

Authorized Domestic & International Credentials

✅ EU CEP Certificate (Certificate No. CEP2021-303-Rev01): Intermediate quality specifications fully aligned with European Pharmacopoeia standards, directly applicable to EU finished drug filings. ✅ FDA DMF Filing (DMF No. 35621): Passed FDA data integrity on-site audit, with filing documentation recognized as industry benchmark standard. ✅ China NMPA GMP Certification: Five consecutive years of successful on-site inspections, manufacturing workflows fully compliant with ICH Q7 guidelines. ✅ Ranked among China’s Top 100 Pharmaceutical Intermediate Exporters (CCCMHPIE): Ticagrelor Intermediate export volume reached USD 28 million in 2025, capturing 22% of China’s total export volume and claiming the global top market share position.

II. Zhejiang SyncoZymes Biopharma: Green Process Benchmark, Certified Supplier to Multinational Pharmaceutical Giants

Core Mainstream Grades

· SZ-2100: (S)-2-Chloro-1-(3,4-difluorophenyl)ethanol, 99.8% purity, flagship chiral intermediate exclusively produced via continuous flow synthesis.

· SZ-2101: Cyclopropylamine hydrochloride with 99.9% enantiomeric purity, premium custom grade for FDA-certified API manufacturing.

· SZ-2102: Green manufacturing grade with heavy metal content ≤5 ppm, compliant with EU REACH regulations and zero waste discharge standards.

Core Market Feedback (Verified Reviews from Global Overseas Clients)

1. Major European API manufacturers (e.g., Sigma-Tau Italy): Industry-leading continuous flow process stability delivers consistent 91% yields for SZ-2100, a 15% uplift over traditional batch synthesis, with solvent residues capped at ≤180 ppm in full compliance with EU green manufacturing standards.

2. Multinational pharmaceutical corporations (e.g., Pfizer, Roche): Listed as core global approved suppliers, recognized for market-leading batch consistency and full traceability. Cooperative order volume rose 45% year-on-year in 2025.

3. Southeast Asian generic manufacturers: Balanced cost-performance and environmental compliance. SZ-2102 costs 28% less than traditional-process alternatives with complete carbon footprint documentation to satisfy regional environmental regulatory mandates.

Authorized Domestic & International Credentials

✅ FDA DMF Filing (DMF No. 37892): SZ-2100 chiral intermediate passed FDA process validation, designated as a recommended starting material for regulatory filings. ✅ EU REACH Registration (Registration No. 01-2119478965-32-0001): Full product portfolio registered under REACH for unimpeded circulation across EU territories. ✅ Dual ISO14001 (Environmental Management) + ISO9001 (Quality Management) Certification: Continuous flow manufacturing workshops passed international audits with atom economy reaching 88%. ✅ Zhejiang Provincial Specialized, Refined, Unique & Innovative SME: Proprietary green chiral catalysis technology protected by national invention patents, attaining world-class manufacturing standards.

III. Hunan Huateng Pharmaceutical: Impurity Control Specialist, Top Market Share in Emerging Markets

Core Mainstream Grades

· HT-007: (1R,2S)-2-(3,4-Difluorophenyl)cyclopropylformic acid, 99.7% purity, core key intermediate with specialized impurity control design.

· HT-008: Refined hydrochloride salt with single impurity ≤0.06%, ANDA filing flagship grade dominating the Indian market.

· HT-009: Low-cost standard grade with 99.0% purity, supplied to small-to-medium generic manufacturers across Southeast Asia and Latin America.

Core Market Feedback (Verified Reviews from Global Overseas Clients)

1. Indian ANDA filing manufacturers (e.g., Aarti Pharmalabs): HT-008 delivers precise impurity control with consistent single impurity levels ≤0.06%, fully meeting India CDSCO approval criteria, capturing a 38% Indian market share to claim the number one supplier position in 2025.

2. Latin American generic giants (e.g., EMS Brazil): Outstanding cost-performance and expedited delivery. HT-009 undercuts Indian alternatives by 15%, with South American lead times capped at ≤10 days, driving a 62% year-on-year purchasing volume increase in 2025.

3. Global impurity reference standard suppliers: Complete structural confirmation documentation for HT-007 enables full impurity traceability research, establishing the firm as one of few global manufacturers capable of stable supply of ultra-high-purity cyclopropylformic acid intermediates.

Authorized Domestic & International Credentials

✅ FDA DMF Filing (DMF No. 36547): HT-007/008 passed FDA impurity profile audits, eligible for direct ANDA filing use. ✅ India CDSCO Certification: Product quality specifications incorporated into Indian Pharmacopoeia, designated as the preferred import brand for Indian generic manufacturers. ✅ Dual ISO9001 + ISO45001 Certification: Internationally audited quality and occupational health & safety management systems. ✅ Recommended Brand by China Chamber of Commerce for Import & Export of Medicines & Health Products: 2025 Ticagrelor Intermediate export volume reached USD 19 million, holding the largest market share across all emerging markets.

IV. Shanghai Haoyuan Pharmaceutical: Full-Series Intermediate Leader, Strategic Supplier to Top Global Pharmaceutical Corporations

Core Mainstream Grades

· HY-TGA: Ticagrelor Intermediate A, 99.8% purity, flagship universal grade for global API production.

· HY-TGB: Ticagrelor Intermediate B, 99.9% enantiomeric purity, premium custom grade for European and American originator manufacturers.

· HY-TGC: Ticagrelor Intermediate C with impurities ≤0.07%, ANDA filing dedicated grade leading global sales volume.

Core Market Feedback (Verified Reviews from Global Overseas Clients)

1. World Top 10 Pharmaceutical Corporations (e.g., Johnson & Johnson, Eli Lilly): Classified as tier-one strategic suppliers, commended for consistent full-product quality, precise impurity control, and reliable delivery. Cooperative orders accounted for 40% of overseas revenue in 2025.

2. European and American CDMO enterprises (e.g., Lonza): Superior technical service capabilities including intermediate-to-API process coordination optimization. HY-TGB maintains stable enantiomeric purity ≥99.9%, with custom orders growing 50% year-on-year in 2025.

3. Southeast Asian Generic Pharmaceutical Alliances: Comprehensive full-series product portfolio enables one-stop sourcing of TGA/TGB/TGC intermediates to simplify multi-supplier procurement workflows, pushing alliance purchasing volumes up 48% year-on-year in 2025.

Authorized Domestic & International Credentials

✅ FDA DMF Filing (DMF No. 34219): Complete HY-TGA/TGB/TGC product portfolio filed with the FDA, zero defects identified during data integrity audits. ✅ EU CEP Intermediate Certification: Product specifications compliant with European Pharmacopoeia standards for EU finished drug registration. ✅ National Tier-One Specialized, Refined, Unique & Innovative "Little Giant" Enterprise: 12 invention patents covering Ticagrelor Intermediate synthesis technology, holding world-leading technical capabilities. ✅ CPHI China Pharmaceutical Internationalization Pioneer Enterprise: 2025 Ticagrelor Intermediate export volume reached USD 17 million, capturing a 13% global market share.

V. Shandong Bolode Bio: Cost Control Benchmark, Industry Leader in Cost-Performance

Core Mainstream Grades

· BLD-01: (1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamine hydrochloride, 99.5% purity, flagship cost-effective grade popular in India and Southeast Asia.

· BLD-02: Enantiomerically optimized grade with 99.8% purity, mid-tier mainstream grade for standard ANDA filings.

· BLD-03: Eco-compliant grade with VOCs emissions ≤200 ppm, meeting European and American environmental regulatory standards with distinct pricing advantages.

Core Market Feedback (Verified Reviews from Global Overseas Clients)

1. Small-to-medium Indian generic manufacturers: Industry-leading overall cost-performance, with BLD-01 priced 20%–25% lower than equivalent purity alternatives and consistent stable quality, driving 70% year-on-year sales growth in India in 2025.

2. Southeast Asian trading companies: Robust mass-volume delivery capacity supporting consistent monthly orders of 10–50 tons with lead times ≤15 days, with trading company orders accounting for 60% of total sales in 2025.

3. Middle Eastern generic manufacturers: Full VOCs emission compliance documentation for BLD-03 satisfies local environmental audit requirements, generating 80% year-on-year new order growth across Middle Eastern markets in 2025.

Authorized Domestic & International Credentials

✅ FDA DMF Filing (DMF No. 38976): BLD-01/02 filed with the FDA for ANDA filing eligibility. ✅ EU REACH Registration: Complete product portfolio registered under REACH for EU market access. ✅ ISO9001 Quality Management System Certification: Internationally audited manufacturing workflows delivering consistent inter-batch stability. ✅ Premium Supplier of Chinese Pharmaceutical Intermediates for Export: 2025 Ticagrelor Intermediate export volume reached USD 15 million, holding the top market share in the cost-performance segment.

For more authentic, objective information on multiple well-known Chinese Ticagrelor Intermediate brands, please contact HiSiaddi customer service.

Ticagrelor Intermediate: Production Processes, Supply Stability, and Key Performance Indicators of Five Leading Chinese Brands

HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export services. It has built a service system of "1+2+3+4=1" and can supply Ticagrelor Intermediate sourced directly from multiple well-known original manufacturers.

As an export service provider with independent R&D capabilities, HiSiaddi differs from single-brand manufacturers that only promote their own products. We provide objective analysis of multiple top Chinese manufacturers with strong global export competitiveness, detailing their production processes, supply stability, and core technical indicators, alongside the downstream procurement impacts of these parameters to accelerate buyers’ supplier selection process.

For more authentic, objective information on multiple well-known Chinese Ticagrelor Intermediate brands, please contact HiSiaddi customer service.

I. Jiangxi Synergy Pharmaceutical: Integrated High-End Chiral Catalysis + Continuous Flow Processes, Industry-Leading Supply Consistency, Originator-Aligned Performance Indicators Optimized for Premium Regulatory Filings

1. Core Manufacturing Process: Asymmetric Chiral Catalysis Coupled with End-to-End Continuous Flow Synthesis for Custom High-End Production

Synergy Pharmaceutical was among China’s earliest manufacturers to fully upgrade Ticagrelor Intermediate production processes, phasing out traditional chemical resolution workflows entirely. Two differentiated process lines support its core TH-001/TH-002/TH-003 grades:

1. Premium Grades TH-001/TH-003 (Originator & Custom Impurity Control): Ruthenium-based recyclable chiral ligand asymmetric catalysis paired with tubular continuous flow reactors. Starting from 3,4-difluorostyrene, recoverable chiral catalysts replace costly, high-pollution stoichiometric resolution reagents. All reaction, extraction, crystallization, and drying stages operate within sealed continuous flow production lines without intermittent material transfer. Process advantages include atom economy exceeding 87%, 40% lower three-waste discharge versus traditional routes, and directional chiral center formation to control isomeric impurities at the source.

2. Standard Grade TH-002 (Generic Mass Production): Optimized batch synthesis paired with precision rectification purification, retaining mature synthetic pathways with upgraded distillation column systems to minimize manufacturing costs for high-volume low-margin orders.

3. Post-Processing Support: All products undergo low-temperature vacuum crystallization and dust-free air drying to eliminate solvent residues and secondary contamination, manufactured within Class D GMP clean workshops.

2. Supply Stability: Dedicated Large-Scale Production Bases with Redundant Production Lines, Zero Delays on Long-Term Framework Orders

1. Capacity Layout: Two dedicated manufacturing sites in Jiangxi operating four exclusive Ticagrelor Intermediate production lines with a total monthly capacity of 55 tons (660 tons annual capacity). Two premium-grade lines serve European/American originator and ANDA filing clients, while two standard lines support global generic demand.

2. Supply Guarantee Protocols: Primary and backup redundant production lines ensure 100% capacity absorption during scheduled maintenance of any single line. Core raw materials are stocked with a three-month safety inventory secured via long-term supply agreements with top domestic chemical manufacturers.

3. Delivery Track Record: 100% on-time delivery performance for all overseas long-term contracts over the past three years. Standard lead times: 10–12 days for Europe and the U.S., 7–9 days for India and Southeast Asia. Capable of fulfilling single batch orders of 20–50 tons and accommodating 30% ad-hoc order volume surges from clients.

4. Risk Mitigation: No seasonal production shutdowns; environmental maintenance scheduled during off-peak periods with zero instances of large-scale supply disruption or capacity rationing.

3. Core Key Performance Indicators: Full-Spec Benchmarks Exceeding EP/USP Pharmacopoeia Standards; Industry-Leading Chiral and Impurity Control

All listed metrics represent standard factory release specifications, exceeding minimum pharmacopoeial requirements set by EP/USP:

1. Chemical Purity: TH-001/TH-003 ≥99.8%, TH-002 ≥99.5%

2. Enantiomeric Purity (Core Metric): All grades ≥99.9%, inter-batch fluctuation ≤0.05% (top-tier industry performance)

3. Maximum Single Impurity: Premium grades ≤0.05%, standard grades ≤0.08%

4. Total Heavy Metals: ≤8 ppm; Solvent Residues (Ethanol, Ethyl Acetate) ≤150 ppm

5. Moisture Content: ≤0.2%; Residue on Ignition ≤0.1%

6. Batch Consistency: Analytical deviation across 20 consecutive production batches <0.1%.

4. Impacts on Downstream Buyers: Optimized for Premium Regulated Global Markets, Reduced Filing Risks and API Rework Rates

1. European/American originator and high-end API manufacturers: Specifications fully match originator raw material benchmarks, with complete DMF/CEP audit documentation to streamline ANDA and EU finished drug filings, eliminating supplementary impurity research requirements and accelerating regulatory approval timelines.

2. Top-tier Indian/Southeast Asian generic manufacturers: Consistent supply with minimal inter-batch variation eliminates repeated API synthesis parameter recalibration, cutting downstream rework rates by over 25% and reducing total comprehensive production costs.

3. Limitations: Premium-grade pricing sits at a premium, unsuitable for ultra-low-cost mass-market generic manufacturers; high minimum order quantities limit flexibility for small-scale trial batches from minor buyers.

II. Zhejiang SyncoZymes Biopharma: Green End-to-End Continuous Flow Core Processes, Regional Warehousing Optimized Delivery, EU Environmental Standard-Aligned Indicators Tailored for European Compliance Markets

1. Core Manufacturing Process: Fully Continuous Flow Green Synthesis with Closed-Loop Solvent Recovery, Specialized Eco-Compliant Production Workflows

Green chemical manufacturing forms SyncoZymes’ core competitive advantage, with flagship SZ-2100/SZ-2101/SZ-2102 grades exclusively manufactured via full continuous flow synthesis integrated with closed-loop solvent recovery systems, replacing traditional batch reactor production entirely:

1. Synthetic Route: Single-step cyclopropylamine synthesis paired with proprietary non-metallic organic chiral catalysts, eliminating heavy metal catalyst usage and associated residual contamination risks from the source.

2. Environmental Support Infrastructure: 92% of reaction solvents recovered and recycled within a closed-loop system; real-time online wastewater and exhaust treatment equipment maintains VOCs emissions far below EU regulatory limits. All production lines integrate carbon footprint monitoring hardware capable of issuing full lifecycle carbon emission reports.

3. Premium Custom Grade SZ-2101: Additional secondary chiral refining processes optimized for impurity separation to satisfy stringent overseas regulatory audit standards.

2. Supply Stability: Zhejiang Main Manufacturing Base + Overseas Regional Bonded Warehouses, Superior European Market Delivery Efficiency

1. Capacity Configuration: Three dedicated continuous flow production lines at the Zhejiang manufacturing base delivering 42 tons monthly capacity (504 tons annual capacity). Highly automated production minimizes manual intervention and equipment failure rates.

2. Warehousing & Delivery Infrastructure: Bonded regional warehouses in the Netherlands and Singapore cover core European and Southeast Asian markets. EU orders ship directly from local inventory, cutting lead times to 4–6 days.

3. Supply Priority Rules: Long-term framework agreement clients receive priority production scheduling with locked capacity allocations; raw material safety inventories maintained at a 2.5-month level.

4. Historical Delivery Performance: 99.2% on-time delivery rate for European clients over the past two years, with minor delays only occurring during extreme global logistics congestion. Eco-aligned manufacturing processes eliminate capacity rationing risks stemming from European environmental policy enforcement.

3. Core Key Performance Indicators: Environmental Metrics as Primary Differentiator; Purity & Impurity Specifications Fully Compliant with EU REACH/CEP Standards

1. Chemical Purity: SZ-2100 ≥99.8%, SZ-2101 ≥99.9%, SZ-2102 ≥99.5%

2. Enantiomeric Purity: ≥99.85%, inter-batch fluctuation ≤0.08%

3. Maximum Single Impurity: ≤0.07%

4. Proprietary Eco Metrics: Total heavy metals ≤5 ppm (industry-leading benchmark), VOCs emissions ≤180 ppm, solvent residues ≤160 ppm

5. Moisture Content ≤0.25%; microbial limits fully compliant with Western pharmacopoeial starting material specifications.

4. Impacts on Downstream Buyers: Unmatched EU Market Entry Advantages, Zero Additional Compliance Expenses for Environmental Audits

1. European API and finished drug manufacturers: Pre-compiled REACH registration, carbon footprint, and low-heavy-metal compliance documentation eliminates additional testing and remediation costs to pass EU environmental regulatory reviews, cementing the firm’s position as the preferred European market supplier.

2. Global generic manufacturers targeting European expansion: Regional bonded warehouses drastically shorten logistics lead times and enable expedited emergency replenishment, ideal for centralized procurement orders with tight delivery deadlines.

3. Limitations: Continuous flow production lines feature low retooling flexibility, limiting customized impurity adjustment capabilities relative to Jiangxi Synergy; pricing lacks competitiveness for low-cost mass-market Indian generic segments.

III. Hunan Huateng Pharmaceutical: Optimized Batch Synthesis with Multi-Stage Purification, Stable Supply for Emerging Markets, South Asian Pharmacopoeia-Aligned Impurity Indicators Focused on India & Latin America

1. Core Manufacturing Process: Mature Optimized Batch Synthesis Coupled with Multi-Stage Column Chromatography Purification, Specialized Impurity Targeted Separation Workflows

Huateng Pharmaceutical specializes in cost-effective impurity-controlled manufacturing, with flagship HT-007/HT-008/HT-009 grades produced via refined traditional batch reactor synthesis paired with two-stage column chromatography purification, without full-scale continuous flow deployment:

1. Core Synthetic Framework: Industry-standard mature cyclopropylamine synthesis routes optimized via precise temperature and pH modulation to boost primary reaction selectivity and minimize byproduct generation.

2. Differentiating Specialized Purification Stage: Dual-stage column chromatography paired with precision membrane filtration engineered to selectively remove specific impurities highlighted in India CDSCO pharmacopoeial guidelines, a purification workflow custom-designed for South Asian market regulatory requirements.

3. Tiered Manufacturing Workflows: HT-008 (ANDA Filing Grade) undergoes an additional recrystallization step; HT-009 (Low-Cost Standard Grade) simplifies purification protocols to minimize manufacturing overhead.

4. Workshop Standards: Standard GMP-compliant manufacturing facilities with wastewater and exhaust treatment infrastructure meeting domestic and Southeast Asian baseline environmental regulations.

2. Supply Stability: Single Large-Scale Manufacturing Base Optimized for Mass-Volume Shipment, Dedicated Logistics Routes for South Asia & Latin America

1. Capacity Scale: Four standard batch production lines at the Hunan manufacturing base delivering 38 tons monthly capacity (456 tons annual capacity). Simple low-maintenance production lines engineered for sustained full-capacity mass manufacturing.

2. Supply Specialization: Prioritizes standardized high-volume long-term orders for Indian and Latin American framework clients; raw material inventories held at a two-month safety level utilizing low-cost bulk industrial feedstocks with minimal supply chain price volatility.

3. Standard Lead Times: India 7–10 days, Latin America 12–15 days, Southeast Asia 8–11 days; minimum order threshold excludes small discrete batches below 500 kg.

4. Supply Risk Vulnerabilities: Annual 1–2 brief scheduled maintenance shutdowns triggered by regional domestic environmental inspections, temporarily reducing capacity by 20% and requiring proactive advance inventory planning from clients.

3. Core Key Performance Indicators: Calibrated to India CDSCO Pharmacopoeia Standards; Balanced Cost-Performance Impurity Control Benchmarks

1. Chemical Purity: HT-007 ≥99.7%, HT-008 ≥99.6%, HT-009 ≥99.0%

2. Enantiomeric Purity: ≥99.8%, meeting mandatory South Asian and Latin American pharmacopoeial thresholds

3. Maximum Single Impurity: HT-008 ≤0.06% (core competitive advantage for Indian market access), HT-009 ≤0.10%

4. Total Heavy Metals ≤10 ppm; Solvent Residues ≤200 ppm; Moisture Content ≤0.3%

5. Specialized Compliance Metric: All region-specific signature impurities specified within the Indian Pharmacopoeia fully controlled with dedicated analytical testing reports available upon request.

4. Impacts on Downstream Buyers: Optimized for South Asian Generic Pharmaceutical Markets, Controllable Long-Term Raw Material Expenses

1. Indian manufacturers pursuing CDSCO ANDA filings: Impurity specifications precisely aligned with local regulatory standards, streamlined regulatory filing documentation workflows establishing Huateng as the top imported intermediate brand for Indian generic producers.

2. Large Latin American and Middle Eastern finished drug manufacturers: Robust mass-volume production capacity paired with moderate unit pricing stabilizes raw material expenditure for low-margin mass-market generic formulations.

3. Limitations: Inferior enantiomeric purity and environmental compliance metrics relative to Jiangxi Synergy and Zhejiang SyncoZymes, disqualifying direct use for premium European and American regulatory filings; periodic capacity reductions during annual maintenance require clients to implement advance inventory planning.

IV. Shanghai Haoyuan Pharmaceutical: Dual Hybrid Process Matrix, Flexible Full-Spectrum Production, Multi-Region Global Capacity Layout, Universal Tiered Product Specifications for All Market Segments

1. Core Manufacturing Process: Parallel Continuous Flow + Batch Synthesis Hybrid Matrix, Flexible Reconfigurable Production Lines for Customized Full-Series Intermediate Development

As an integrated CDMO and intermediate supplier, Haoyuan deploys dual parallel manufacturing workflows split across its three core HY-TGA/HY-TGB/HY-TGC product grades:

1. Premium Grade HY-TGB (Originator & Western ANDA Filing): Chiral catalysis paired with compact continuous flow synthesis plus advanced deep refining processes prioritizing ultra-high quality and full audit traceability.

2. Standard Universal Grades HY-TGA/HY-TGC (Global API Mass Production): Mature optimized batch synthesis with high process tolerance to support flexible low-volume multi-specification custom manufacturing.

3. Customization Support Infrastructure: All production lines integrate configurable process adjustment interfaces enabling on-demand modification of synthesis and purification workflows to develop custom impurity profiles and unique product specifications, delivering the broadest manufacturing flexibility among the five manufacturers analyzed.

2. Supply Stability: Dual Manufacturing Bases in Shanghai & Jiangsu, Flexible Capacity Accommodating All Batch Sizes, Globally Balanced Delivery Performance

1. Capacity Layout: Five total production lines split across Shanghai and Jiangsu manufacturing facilities delivering 35 tons monthly capacity (420 tons annual capacity). Highly reconfigurable flexible lines enable rapid switching between distinct product specifications.

2. Unique Supply Advantages: No minimum order quantity restrictions, supporting trial batches as small as 100 kg alongside mass-volume orders up to 30 tons; balanced production scheduling evenly allocates output across European, Indian, and Southeast Asian client bases.

3. Inventory & Delivery Protocols: Core raw materials held across dual-site inventories with a combined 2.8-month safety stock; global average delivery lead times range from 8–14 days.

4. Historical Stability Performance: Group-level integrated supply chain infrastructure minimizes supply disruption risks; high volumes of custom orders extend standard mass-production order lead times by 2–3 days during peak capacity utilization.

3. Core Key Performance Indicators: Tiered Specifications Covering Premium and Standard Market Segments; Industry-Most Comprehensive Regulatory Audit Documentation Library

Three distinct performance tiers cover all downstream buyer requirements:

1. Premium HY-TGB Grade: Chemical Purity ≥99.85%, Enantiomeric Purity ≥99.9%, Single Maximum Impurity ≤0.06%

2. Mid-Tier Universal HY-TGA/HY-TGC Grades: Chemical Purity ≥99.6%, Enantiomeric Purity ≥99.85%, Single Maximum Impurity ≤0.07%

3. Cross-Grade Universal Benchmarks: Total Heavy Metals ≤9 ppm; Solvent Residues ≤170 ppm; Moisture Content ≤0.22%

4. Unique Competitive Advantage: Full batch documentation packages including process validation, data integrity certification, and complete impurity traceability records, unmatched in comprehensiveness across the industry.

4. Impacts on Downstream Buyers: One-Stop Sourcing & Integrated Technical Support for Diversified Procurement Requirements

1. Global CDMOs and small-to-medium API manufacturers: Complete full-spectrum intermediate portfolios enable consolidated single-supplier sourcing to eliminate multi-vendor coordination overhead; flexible small-batch trial production perfectly supports generic and new drug R&D-stage clients.

2. Cross-Border trading companies: Diverse product specifications and complete regulatory documentation enable full coverage of all regional market client requirements, mitigating cross-border compliance risks.

3. Limitations: Standard mass-volume order unit pricing exceeds Huateng and Bolode; fully saturated flexible production lines extend standard order lead times by 2–3 days.

V. Shandong Bolode Bio: Ultra-Optimized Traditional Batch Synthesis, Large-Scale Mass Production, Cost-First Performance Benchmarks Focused on Low-End Mass-Market Segments

1. Core Manufacturing Process: Classic Batch Reactor Synthesis with Simplified Purification, Cost-Minimized Mass Production Workflows for Low-Price Standard Grades

Bolode exclusively targets cost-effective mass-market production, with all BLD-01/BLD-02/BLD-03 grades manufactured via mature traditional batch reactor synthesis without capital-intensive continuous flow or precious metal chiral catalysis infrastructure investment:

1. Synthetic Route Design: Lowest-cost domestically standardized synthetic pathways utilizing minimal reaction stages to compress production labor and cycle time.

2. Tiered Purification Protocols: Flagship mass-volume grade BLD-01 undergoes only single recrystallization plus standard filtration to minimize manufacturing overhead; BLD-02/BLD-03 add one basic refining stage to meet mid-tier regulatory compliance benchmarks.

3. Environmental Compliance Infrastructure: Baseline three-waste treatment equipment meeting minimum domestic, Southeast Asian, and Middle Eastern environmental standards, without high-investment closed-loop solvent recovery hardware.

2. Supply Stability: Single Manufacturing Base Operating at Full Continuous Capacity, Priority Allocation for Large-Volume Orders, Limited Small-Batch Responsiveness

1. Capacity Scale: Three high-throughput batch production lines at the sole Shandong manufacturing base delivering 32 tons monthly capacity (384 tons annual capacity), operating year-round at maximum utilization dedicated exclusively to standardized mass-volume production.

2. Supply Scheduling Rules: Orders exceeding 10 tons receive top production priority; batches below 5 tons are deprioritized in scheduling. Raw material sourcing relies on low-cost bulk industrial feedstocks with minimal price fluctuation exposure.

3. Standard Lead Times: India & Middle East 7–11 days; Southeast Asia 9–13 days.

4. Supply Risk Vulnerabilities: Low technical manufacturing barriers create peak-season order backlogs with minor declines in inter-batch testing consistency; no capacity to accommodate complex custom impurity development requests.

3. Core Key Performance Indicators: Minimum Compliance-Focused Benchmarks Optimized for Low-Cost Generic Market Segments

All specifications engineered to meet baseline regulatory compliance thresholds while minimizing manufacturing costs, without pursuit of ultra-high technical benchmarks:

1. Chemical Purity: BLD-01 ≥99.5%, BLD-02 ≥99.7%, BLD-03 ≥99.4%

2. Enantiomeric Purity: ≥99.7%, meeting only minimum market entry thresholds for India and Southeast Asian regulatory frameworks

3. Maximum Single Impurity: ≤0.10%

4. Total Heavy Metals ≤12 ppm; Solvent Residues ≤220 ppm; Moisture Content ≤0.35%

4. Impacts on Downstream Buyers: Maximum Raw Material Cost Reduction for Low-Tender Mass-Market Formulations, Exclusion from Premium Regulated Western Markets

1. Small-to-medium generic manufacturers in India, the Middle East, and Southeast Asia: Industry-low unit pricing drastically cuts raw material expenditure, maximizing profit margins for low-bid centralized procurement mass-market generic formulations.

2. Low-tier cross-border trading companies: Abundant mass-volume inventory enables fast regional distribution turnover for commodity-grade pharmaceutical intermediates.

3. Significant Limitations: Substandard enantiomeric purity, impurity control, and environmental compliance metrics disqualify products from European, American, and Japanese premium regulated markets; minimal flexibility for small trial batches or custom impurity specification development; minor inter-batch consistency degradation during peak seasonal production occasionally causes minor downstream API quality fluctuations.

For more authentic, objective information on multiple well-known Chinese Ticagrelor Intermediate brands, please contact HiSiaddi customer service.

Ticagrelor Intermediate: Key Factors for Buyers to Consider When Purchasing Based on HiSiaddi’s Market Experience

As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials from multiple well-known original manufacturers for Ticagrelor Intermediate. As a foreign trade enterprise with R&D capabilities, HiSiaddi will analyze key purchasing considerations and critical indicators from a professional perspective to ease procurement concerns.

If you require more professional and in-depth analysis regarding the procurement of Ticagrelor Intermediate, please contact HiSiaddi’s customer service team.

I. Comprehensive Considerations for Procuring High-Grade Ticagrelor Intermediates from a Global Sourcing Perspective

High-grade Ticagrelor intermediates are high-end chiral heterocyclic pharmaceutical fine chemicals without high-risk properties such as flammability, explosiveness or strong corrosiveness. They are uniformly classified as pharmaceutical solid fine chemicals in most countries worldwide. The products are subject to multiple regulatory constraints including the REACH Regulation, ICH impurity control guidelines, pharmacopoeia standards of various countries, pharmaceutical GMP, residual solvent classification, genotoxic substances, microbial limits and endotoxins. Their core quality is determined by chemical purity, chiral purity (ee value), related substances (single impurity / total impurities), residual solvents, genotoxic impurities, heavy metals, water content, crystal form, particle size and chemical stability.

Such chiral heterocyclic intermediates are extremely sensitive to trace impurities and chiral isomers. Once indicators go out of specification, they will trigger a sharp surge of by-products in downstream synthesis, disqualify APIs in chiral testing, raise risks to medication safety, and even lead to failures in overseas drug registration and pharmaceutical authority audits. Significant discrepancies exist in pharmacopoeia standards, residual solvent limits and genotoxic substance control requirements across different regions and countries. Therefore, procurement cannot rely solely on unit price comparison; instead, selections must be comprehensively evaluated by combining internal synthetic routes, drug R&D/commercial production stages, pharmaceutical regulations of target markets and production equipment operating conditions.

(I) Compliance Qualification Verification: Align with Global Pharmaceutical Regulations to Ensure Smooth Customs Clearance, Production and Drug Registration

Compliance certificates and supporting documents serve not only as the foundation for smooth cross-border customs clearance but also as core evidence for downstream drug manufacturing, overseas registration and internal GMP audits of clients. They constitute the primary verification item prior to cooperation.

1. Special Certifications and Test Reports Matched by Application Scenarios

· R&D trial-grade products for preclinical research and laboratory process optimization: REACH registration, full SVHC screening reports, alongside basic heavy metal and routine residual solvent test data to meet general control requirements for pharmaceutical raw materials.

· Commercial pharmaceutical production-grade products for mass manufacturing of Ticagrelor APIs and clinical batch production at home and abroad: Complete GMP production qualifications, pharmaceutical intermediate production licenses, plus test reports for ICH Q3A/Q3B related substance analysis, ICH Q3C residual solvent classification and heavy metal limit inspection, fully complying with pharmacopoeia standards of mainstream markets including Europe, the US, Japan and South Korea.

· Clinical/injection auxiliary-grade products for synthesis of injectable formulations and high-purity clinical drugs: Supplementary test reports for microbial limits, bacterial endotoxins, sterility and exogenous contaminant screening.

· Registration custom-grade products for overseas new drug registration, official pharmaceutical authority audits and high-end customized CDMO projects: Full qualitative and quantitative impurity analysis, special genotoxic impurity screening, chiral structure confirmation (NMR/MS/IR spectra), crystal form identification and full-cycle stability study reports, with support for clients’ pharmaceutical raw material filing and document submission in target countries.

1.

Complete Documents for Cross-Border Customs Clearance and Trade The product is solid crystalline powder, not classified as hazardous chemicals, and follows global general transportation rules for common pharmaceutical solids. We uniformly provide multi-lingual SDS safety data sheets and chemical hazard classification identification reports. Standard customs clearance documents include certificates of origin, batch-by-batch full-item COA quality inspection reports, complete batch production records and product traceability slips. For pharmaceutical production-grade and registration custom-grade orders, supplementary supporting materials include HPLC purity & related substance chromatograms, chiral chromatograms, GC residual solvent chromatograms, ICP heavy metal test reports and original structure confirmation spectra, satisfying audit requirements of overseas pharmaceutical enterprises and regulatory authorities.

2.

3.

Supplier Comprehensive Qualification Screening Priority shall be given to original manufacturers with integrated capabilities in heterocyclic synthesis, chiral center construction, multi-stage refining and GMP clean production as well as full-range impurity research. Key verification items include third-party pharmaceutical testing institution qualifications, traceability of test data and spectra, and long-term cooperation cases with overseas pharmaceutical clients. The core technical challenges of this product category lie in maintaining chiral configuration, removing heterocyclic by-products and controlling high-risk solvent residues. Suppliers with insufficient process control capabilities are prone to issues such as chiral racemization, excessive related substances and detectable genotoxic impurities, which may directly cause pharmaceutical quality incidents and trade claims. Prior to formal cooperation, factory qualification audits, small-batch synthesis trials and full-indicator re-inspection by international third-party laboratories must be completed to confirm process compatibility before mass collaboration.

4.

(II) Raw Material and Production Process Inspection: Stabilize Product Quality and Reaction Performance via Chiral Synthesis & Purification Procedures

Chemical purity, chiral stability, impurity distribution and shelf life of finished products are fundamentally determined by the grade of starting materials, chiral catalytic systems, heterocyclic synthesis processes, recrystallization/chromatography purification, low-temperature vacuum drying and other key procedures—these also serve as the core criteria to distinguish different quality grades.

1.

Upstream Raw Material Quality Inspection High-quality products adopt high-purity heterocyclic starting materials, high-selectivity chiral catalysts and pharmaceutical-grade low-toxic solvents to complete directional synthesis in a closed clean reaction system, restraining side reactions and impurity generation from the source. Subsequent multi-stage preparative chromatography, gradient recrystallization, targeted solvent removal and high-vacuum low-temperature drying thoroughly separate racemates, unreacted raw materials, heterocyclic by-products and residual organic solvents. Finished products feature stable chiral configuration, high purity and ultra-low impurity content; they resist racemization and degradation under long-term refrigerated storage and demonstrate excellent compatibility with the full synthetic route of Ticagrelor. Low-grade products adopt industrial-grade raw materials with simplified purification and drying processes, commonly suffering from insufficient chiral purity, excessive heterocyclic by-products, out-of-limit residual solvents and easy degradation at ambient temperature, rendering them completely unfit for pharmaceutical mass production and overseas drug registration. When purchasing high-end pharmaceutical grades, buyers may request suppliers to provide quality certificates for starting materials, catalysts and reaction solvents.

2.

3.

Classification and Confirmation of Core Production Processes Main complete process route: High-purity raw material pretreatment → Chiral catalysis + directional heterocyclic synthesis → Multi-step functional group transformation reaction → Crude product filtration enrichment → Multi-stage chromatography / recrystallization for heterocyclic impurity and racemate removal → In-depth residual solvent stripping → High-vacuum low-temperature drying → Sieving (as required) → Nitrogen-sealed packaging → GMP constant-temperature warehousing.

4.

· R&D trial grade: Standard synthesis + two-stage recrystallization, cost-effective, only for laboratory small-scale trials and process development.

· Pharmaceutical production grade: Multi-stage refining + in-depth chiral resolution + targeted solvent removal with strict control of various impurities, suitable for large-scale commercial production.

· Clinical/injection auxiliary grade: Full-process production in sterile clean workshops with additional sterile filtration and endotoxin control procedures to meet high-purity pharmaceutical scenarios.

· Registration custom grade: Ultimate purification + full impurity research + crystal form locking, with complete stability and structural data, exclusively for overseas pharmaceutical registration and audit projects. Formal production lines implement separate production management by grade; high-end pharmaceutical and registration grades are equipped with dedicated equipment and clean areas to avoid cross-contamination between different grades, prohibiting the delivery of low-grade products falsely labeled as high-purity pharmaceutical grade.

1. Quality Control and Batch Consistency Evaluation This pharmaceutical fine chemical adopts batch intermittent production. R&D grades are available off-the-shelf, while production grades, sterile auxiliary grades and registration custom grades are produced against orders with exclusive batch management. Buyers are advised to request multi-batch COAs, HPLC spectra, chiral test data, residual solvent, water content and heavy metal reports, focusing on monitoring fluctuation ranges of chemical purity, chiral ee value, single impurity, total related substances, residual solvents and water content across batches. For long-term cooperation, raw material standards, production processes and test methods can be fixed to guarantee consistent downstream synthesis yield and product quality across batches. Meanwhile, suppliers shall provide normal-temperature, refrigerated and accelerated stability test data to adapt to ocean shipping and warehousing environments with varying temperature and humidity worldwide. Prioritize manufacturers with full independent in-house production capacity; sources purchasing crude products only for simple packaging exhibit severe fluctuations in impurity and chiral indicators, posing major medication safety risks.

(III) Grade and Specification Selection: Match Drug Stages & Synthesis Equipment to Avoid Parameter Mismatch Risks

Ticagrelor high-grade intermediates are categorized into different specifications based on purity grades, chiral indicators, impurity control thresholds, microbial/endotoxin requirements. Incorrect selection will directly interrupt synthesis processes, lead to API scrapping and delay project timelines; precise matching against drug R&D stages, synthesis equipment and target market standards is mandatory.

1. Grade Classification by Application Scenario

· R&D trial grade: For preclinical research, laboratory formulation debugging and small-batch trial production.

· Pharmaceutical production grade: For commercial manufacturing of Ticagrelor APIs and clinical batch production worldwide.

· Clinical/injection auxiliary grade: For synthesis of injectable drugs and high-purity clinical pharmaceutical procedures.

· Registration custom grade: For overseas new drug registration, pharmaceutical authority audits and high-end customized CDMO projects. Cross-substitution of different grades is strictly prohibited.

1.

Physical Form and Process Compatibility Products are available as fine powder and crystalline particles: Fine powder dissolves rapidly, compatible with laboratory reactors and intermittent synthesis processes; crystalline particles feature good fluidity and low dust generation, suitable for closed continuous mass production equipment. Crystal form and particle size distribution shall be specified according to synthesis process requirements, as crystal form changes directly affect dissolution rate, reaction activity and difficulty of downstream purification—this is a key focus in mass production.

2.

3.

Core Indicator Agreements in Contracts Procurement contracts must specify main chemical purity, chiral ee value, maximum single related substance, total related substances, classified residual solvents, water content, heavy metals (Pb/As/Cd/Hg, etc.), ignition residues and corresponding allowable deviations. Additional clauses for microbial limits and bacterial endotoxins shall be added for clinical/injection auxiliary grades; genotoxic impurities, crystal form standards and full sets of structural spectra shall be supplemented for registration custom grades. All indicators shall align with pharmacopoeia standards of target markets and ICH specifications, serving as legal basis for goods acceptance and dispute resolution upon arrival.

4.

5.

Packaging and Minimum Order Rules General packaging for pharmaceutical solid intermediates adopts double-layer pharmaceutical PE bags + aluminum foil vacuum sealing, wrapped in thickened pharmaceutical fiber drums externally. Clinical and registration grades use independent sterile aluminum vials filled with high-purity nitrogen to isolate air and moisture. Units of measurement in the industry include grams and kilograms; flexible small minimum orders are available for R&D grades, while minimum order quantities and production cycles for production and custom grades are agreed upon per project. Small sample verification must be completed before formal mass orders, including solubility testing, full synthetic route small trials and short-term stability observation.

6.

(IV) Commercial Clauses and Full-Lifecycle Cost Accounting: Calculate Total Usage Cost Based on High-Value Pharmaceutical Raw Material Properties

Ticagrelor high-grade intermediates involve complex synthesis, chiral purification and full-item testing procedures, qualifying as high-value pharmaceutical raw materials. Unit price alone cannot serve as the comparison standard; full-lifecycle comprehensive usage cost shall be calculated by integrating product purity, chiral stability, impurity levels, downstream synthesis yield, API qualification rate and drug registration approval rate.

1. International Trade Quotation Modes

· FOB China Port: Quotation covers goods, pharmaceutical-grade packaging, domestic GMP warehousing, pharmaceutical commodity inspection and export filing fees. International transportation, insurance, destination port customs clearance and local pharmaceutical filing are borne by buyers. Suitable for long-term bulk procurement by large pharmaceutical groups and leading CDMOs with optimal comprehensive costs.

· CIF Destination Port: Quotation includes full ocean freight (including pharmaceutical cold chain), cargo insurance, port charges, documents and special pharmaceutical raw material handling fees. The supplier coordinates the entire process for simple operation, suitable for overseas small and medium-sized pharmaceutical enterprises, R&D institutions and pharmaceutical traders with first-time cooperation and small & medium batch orders. Volume tiered pricing and annual long-term framework agreements are available to stabilize long-term supply prices.

1.

Payment Terms, Lead Time and Dispute Definition Mainstream international trade settlement methods include T/T and irrevocable letters of credit. R&D trial grades are in sufficient stock with short lead times; pharmaceutical production grades, clinical auxiliary grades and registration custom grades require longer production cycles due to multi-stage refining, full-item pharmaceutical testing and GMP batch record collation. Contracts shall define dispute judgment criteria: substandard chemical purity / chiral ee value, out-of-limit related substances / residual solvents / genotoxic impurities, unqualified microorganisms / endotoxins, abnormal crystal forms and mismatched goods. Agree on internationally recognized third-party pharmaceutical testing institutions, re-inspection procedures, return & exchange and compensation rules. Meanwhile, clarify that slight caking under normal refrigerated sealed storage is a physical phenomenon without impact on reaction and usage to clearly divide liabilities of both parties.

2.

3.

Warehousing Requirements and Minimum Order Management General storage requirements for all grades: 2~8°C refrigeration, cool & light-shielded environment, fully sealed, away from heat sources, humid conditions, oxidants, strong acids and strong alkalis. Clinical and registration grades must be stored in dedicated pharmaceutical cold chain warehouses with strict compliance with GMP warehousing specifications. Original packaging shall not be split to avoid introduction of exogenous impurities. Agree on free domestic warehousing periods between both parties; prolonged storage of goods at high temperatures or open-air port yards is prohibited.

4.

(V) Packaging, Storage, Transportation and Logistics Control: Follow Pharmaceutical Solid & Cold Chain Standards for Constant Temperature, Sealing, Light Shielding and Anti-Contamination

Core risks during storage and transportation of this product: High temperature and light trigger chiral racemization, heterocyclic structure degradation and increased impurities; moisture absorption alters physical properties; damaged packaging introduces exogenous impurities and microorganisms. The entire process complies with international pharmaceutical raw material cold chain logistics specifications with core control principles: Constant refrigerated temperature, vacuum sealing, light shielding and cross-contamination prevention.

1. Packaging Standards

· General grades: Inner double-layer pharmaceutical PE bag sealing, middle aluminum foil vacuum pumping to isolate air and moisture, outer thickened pharmaceutical fiber drums marked with product name, grade, batch number, storage conditions and expiry date.

· Clinical and registration custom grades: Independent sterile aluminum vial packaging filled with nitrogen under full sterile operation. All packaging undergoes tightness, drop resistance and anti-contamination testing before factory release.

1.

Transportation Control Pharmaceutical production grades, clinical auxiliary grades and registration grades uniformly adopt pharmaceutical constant-temperature cold chain logistics; ocean shipping uses cold chain containers maintained at 2~8°C, avoiding equatorial high-temperature zones. Air freight is declared separately for pharmaceutical solid raw materials with priority cold chain air channels. R&D grades may adopt conventional constant-temperature freight. Cooperating logistics providers must hold pharmaceutical raw material transportation qualifications; full shipments are covered by sufficient cargo insurance with traceable full-process temperature data and logistics trajectories. Transit warehouses feature independent dedicated pharmaceutical cold chain zones; mixing with ordinary chemicals and toxic materials is prohibited.

2.

3.

On-Site Usage Specifications Upon arrival at the port, goods shall be immediately transferred to pharmaceutical cold chain warehouses with intact sealed packaging intact. Sampling and feeding operations shall be completed in clean workshops with pharmaceutical-grade protective equipment worn. After opening and taking materials, re-vacuum seal immediately and return to cold chain storage. Separate storage is required for different grades and production batches with complete inbound and outbound ledgers and temperature records to meet GMP audit requirements.

4.

(VI) Technical Support and After-Sales Service: Focus on Synthetic Processes & Pharmaceutical Registration to Resolve Quality and Documentation Issues

All indicators of this intermediate directly affect multi-step downstream synthesis efficiency and API quality of Ticagrelor; supporting test spectra and batch records also constitute core materials for overseas pharmaceutical authority audits and internal client audits. Full-process technical and documentation services are particularly critical.

1.

Synthetic Process Technical Support We provide samples, complete technical manuals, full-batch test spectra and application cases, recommending optimal feeding ratios, reaction temperatures and storage solutions aligned with clients’ synthetic routes, reaction parameters and equipment types. Process optimization schemes are provided for common issues including reduced chiral purity, abnormal elevation of heterocyclic impurities, low synthetic yield and storage degradation. Meanwhile, we interpret pharmaceutical regulations of target countries, ICH impurity control requirements, residual solvent limits and pharmaceutical intermediate access rules.

2.

3.

Post-Arrival Re-Inspection Coordination Sampling shall follow international pharmaceutical raw material sampling standards. Clients may self-inspect basic indicators such as appearance, water content and solubility, or entrust international third-party pharmaceutical laboratories to re-test core items including chemical purity, chiral ee value, related substances, residual solvents, heavy metals, microorganisms and endotoxins. If test results fail to meet contractual agreements, processing will follow pharmaceutical raw material traceability procedures and compensation rules.

4.

5.

Compliance Document and Registration Data Support Multi-lingual SDS, full COAs, original test spectra, GMP batch records, structure confirmation data and qualification certificates can be provided on demand to assist clients with local pharmaceutical raw material filing, pharmaceutical authority audits and new drug registration document compilation. We also update the latest global information on cardiovascular drug intermediates, ICH regulations and pharmacopoeia standards of various countries.

6.

II. Core Indicators to Prioritize for Buyers by Application Scenario

Based on mainstream global application scenarios, five categories are defined: Preclinical R&D & laboratory small trials, commercial drug mass production, clinical/injectable drug synthesis, overseas new drug registration & CDMO customization, and international pharmaceutical intermediate distribution. Key control points for each scenario are clarified below.

(I) Buyers for Preclinical R&D & Laboratory Small Trials

Core priorities: Stable basic purity and chirality, compliant water content, short-term storage stability, compatibility with multiple experimental conditions

1. Chemical purity with minimal batch fluctuation to meet basic laboratory synthesis requirements

2. Stable chiral ee value without obvious racemization

3. Water content and ignition residues controlled within conventional limits without interfering with experimental reaction systems

4. Routine residual solvents complying with general pharmaceutical raw material standards

5. Stable solubility and crystal form compatible with multiple laboratory processes

6. No significant deterioration of all indicators under short-term refrigerated storage

(II) Buyers for Commercial Drug Mass Production

Core priorities: High chemical purity, high chiral ee value, low single & total impurities, compliant residual solvents, strong batch consistency

1. Chemical purity as core basic indicator with extremely narrow batch-to-batch deviation

2. Chiral ee value as mandatory core indicator to strictly inhibit racemate generation and guarantee qualified stereostructure of APIs

3. Strict control of maximum single impurity and total related heterocyclic by-products to ensure medication safety for end products

4. All residual solvents fully complying with ICH Q3C solvent classification and limit requirements

5. Heavy metals (lead, arsenic, cadmium, mercury, etc.) strictly following general limits for pharmaceutical raw materials

6. Long-term stability: Purity, chirality and impurity indicators remain stable during refrigerated storage over mass production cycles

(III) Buyers for Clinical / Injectable Drug Synthesis

Core priorities: Sterility, low endotoxin, compliant microorganisms, stricter full impurity control, no exogenous contamination

1. Microbial limits and sterility testing as core control items to meet high-purity medication requirements for injections and clinical use

2. Stringent bacterial endotoxin limits to avoid safety risks for injectable medications

3. Internal control standards for chemical purity, chiral ee value and related substances higher than conventional production grades

4. Further tightened limits for residual solvents and heavy metals across all indicators

5. Undetectable exogenous particulate matter and heterobacteria to maintain high-purity production systems

6. Aseptic packaging with full sealing protection to prevent secondary contamination during storage and transportation

(IV) Buyers for Overseas New Drug Registration & CDMO Customization

Core priorities: Traceable full indicators, full impurity characterization, undetected genotoxic impurities, fixed crystal form, complete documentation package

1. Accurate chemical purity and chiral ee value supported by complete original HPLC and chiral chromatogram spectra

2. Full qualitative and quantitative analysis of all related substances with comprehensive impurity research reports

3. Genotoxic impurities as a veto indicator, must be undetected

4. Residual solvents and heavy metals meeting dual standards of ICH and target national pharmacopoeias

5. Fixed crystal form and particle size distribution with authoritative crystal form identification reports

6. Complete structural confirmation data, GMP batch records and long-term stability reports directly usable for pharmaceutical authority audits

(V) Buyers for International Pharmaceutical Intermediate Distribution

Core priorities: Stable cold chain storage & transportation, intact contamination-proof packaging, complete compliance documents, universal applicability

1. Stable storage & transportation performance: No abnormal fluctuations in purity, chirality and impurities after ocean cold chain shipping and multi-country transit

2. Intact vacuum/nitrogen-sealed packaging without moisture absorption, damage, powder leakage or contamination

3. Strong anti-racemization and anti-degradation performance with stable quality under long-term conventional refrigerated storage

4. Basic physical and chemical indicators complying with corresponding grade standards with clear traceable batches

5. Complete supporting documents including SDS, COAs, spectra and qualification traceability materials for cross-border customs clearance and downstream client audits

For more professional and in-depth analysis regarding the procurement of Ticagrelor Intermediate, please contact HiSiaddi’s customer service team.